Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Broadcom forecasts quarterly revenue below estimates
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Jefferies Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 3:47 PM EDTJefferies analyst Roger Song downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold with a price target of $1.50 (from $11.00).
The analyst comments "We spoke w/ mgmt following IDMC demonstrated nab-sirolimus (mTOR) tumor agonostic pivotal in TSC1/TSC2 tumors was unlikely to... More
TD Cowen Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 4:47 AM EDTTD Cowen analyst Boris Peaker downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold.
The analyst comments "Aadi management announced that the PRECISION1 trial in TSC1/2 solid tumors will be discontinued due to low probability of meeting the efficacy threshold needed for accelerated... More
